Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Reply to K.I. Pritchard.

Henry NL, Stearns V.

J Clin Oncol. 2013 Dec 10;31(35):4476-7. doi: 10.1200/JCO.2013.52.7648. Epub 2013 Nov 4. No abstract available.

PMID:
24190127
2.

Symptoms and cancer outcome in adjuvant endocrine therapy for breast cancer: why are they associated?

Pritchard KI.

J Clin Oncol. 2013 Dec 10;31(35):4476. doi: 10.1200/JCO.2013.52.4280. Epub 2013 Nov 4. No abstract available.

PMID:
24190125
3.

Treatment-emergent effects may predict benefit from endocrine therapy.

Henry NL, Stearns V.

J Clin Oncol. 2013 Jun 20;31(18):2233-5. doi: 10.1200/JCO.2013.48.9153. Epub 2013 Apr 22. No abstract available.

PMID:
23610120
4.

Reply to K.I. Pritchard.

Fontein DB, van de Velde CJ; International Tamoxifen Exemestane Adjuvant Multinational (TEAM) Global Steering Committee.

J Clin Oncol. 2013 Dec 10;31(35):4477-9. doi: 10.1200/JCO.2013.53.1707. Epub 2013 Nov 4. No abstract available.

PMID:
24190123
5.

Exemestane or tamoxifen?

Ueda M, Toji E, Noda S.

Lancet. 2007 May 12;369(9573):1600; author reply 1600-1. No abstract available.

PMID:
17499595
6.

Adjuvant treatment of breast cancer with exemestane.

Tanvetyanon T.

N Engl J Med. 2004 Jul 1;351(1):100-2; author reply 100-2. No abstract available.

PMID:
15237463
7.

[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].

Tuxen MK, Nielsen DL, Lindberg H, Kamby C.

Ugeskr Laeger. 2007 Jan 22;169(4):297-9. Review. Danish.

PMID:
17274922
8.

Getting a grip on aromatase inhibitor-associated arthralgias.

Hershman DL.

J Clin Oncol. 2008 Jul 1;26(19):3120-1. doi: 10.1200/JCO.2008.16.7684. Epub 2008 May 12. No abstract available.

PMID:
18474872
9.

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.

Gandhi S, Verma S.

Breast Cancer Res Treat. 2007 Nov;106(1):1-9. Epub 2007 Jan 9. Review.

PMID:
17211535
10.

Bone safety of aromatase inhibitors versus tamoxifen.

Lønning PE.

Int J Gynecol Cancer. 2006;16 Suppl 2:518-20. Review.

PMID:
17010062
11.
12.

A 62-year-old woman with a new diagnosis of breast cancer.

Come SE.

JAMA. 2006 Mar 22;295(12):1434-42. No abstract available.

PMID:
16551716
13.

Extended adjuvant therapy for breast cancer--how much is enough?

Prowell TM, Stearns V.

J Natl Cancer Inst. 2007 Dec 19;99(24):1825-7. Epub 2007 Dec 11. No abstract available.

PMID:
18073372
14.

Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer.

Baumgart J, Nilsson K, Stavreus-Evers A, Kask K, Villman K, Lindman H, Kallak T, Sundström-Poromaa I.

Am J Obstet Gynecol. 2011 Jan;204(1):26.e1-7. doi: 10.1016/j.ajog.2010.08.035. Epub 2010 Oct 14.

PMID:
20950790
15.

Letrozole or tamoxifen in early breast cancer.

Buzdar AU, Baum M, Cuzick J.

N Engl J Med. 2006 Apr 6;354(14):1528-30; author reply 1528-30. No abstract available.

16.

Death due to liver failure during endocrine therapy for premenopausal breast cancer.

Rabaglio M, Ruepp B; Soft/Text/Perche Steering Committee.

Acta Oncol. 2010 Aug;49(6):874-6. doi: 10.3109/0284186X.2010.484813. No abstract available.

PMID:
20482225
17.

Cancer: some reasons to be hopeful.

[No authors listed]

Lancet. 2007 Feb 17;369(9561):531. No abstract available.

PMID:
17307079
18.
19.

[For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].

Jonat W.

MMW Fortschr Med. 2006 Mar 23;148(12):10. German. No abstract available.

PMID:
16625996
20.

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A.

J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. Review.

PMID:
21743022

Supplemental Content

Support Center